Developing precision therapeutics, this company targets the core symptoms of Autism Spectrum Disorder (ASD), such as social interaction difficulties. Their approach aims to provide effective treatments for individuals with ASD.
Funding
$177.4K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Autism Spectrum Disorder (ASD) presents challenges in social interaction and communication, impacting individuals' daily lives. Current therapeutic options often fail to address the core symptoms of ASD effectively. This results in a significant unmet need for targeted treatments that can improve social functioning and overall quality of life for individuals with ASD.
Solution
Translation-X is developing novel therapeutics specifically designed to address the core symptoms of Autism Spectrum Disorder (ASD). Their approach focuses on identifying and targeting the underlying biological mechanisms that contribute to social interaction difficulties and other key challenges associated with ASD. By developing precision therapeutics, Translation-X aims to provide effective treatments that can improve social communication, reduce repetitive behaviors, and enhance overall adaptive functioning in individuals with ASD.
Target Audience
The primary target audience includes individuals diagnosed with Autism Spectrum Disorder (ASD) and their families, as well as healthcare professionals specializing in autism treatment and research.
Features
- Focus on therapeutics for Autism Spectrum Disorder (ASD)
- Targets core symptoms such as social interaction difficulties
- Development of novel treatments